

iCARE Respiratory Program Cuts Hospitalisations by 67% and Lowers Total Cost of Care by 46% in Real-World COPD and Asthma Population

- Adherium's Hailie® Smartinhaler® platform drives breakthrough outcomes in the iCARE real-world study – with findings presented at the Big Sky Pulmonary Conference, Montana, 5 March 2026, demonstrating dramatic reductions in hospitalisations and cost of care.
- Key highlights included a 67% reduction in hospitalisations, a 57% reduction in length of hospital stay, a 46% reduction in total cost of care, and average annual savings of \$12,943 per patient.
- The Hailie® Smartinhaler® platform drove strong real-world adherence: patients achieved typical adherence of nearly two-thirds, with nearly 4 in 10 achieving >80% adherence, a level linked to meaningfully fewer respiratory attacks and hospital admissions.
- iCARE study also demonstrated 54% platform persistence over 14 months, reflecting sustained engagement even among older, higher-risk patients.
- These compelling real-world results together with the growth of the Remote Patient Monitoring channel, validate the Hailie® Smartinhaler® platform's ability to improve patient outcomes at scale, positioning Adherium to secure value-based care contracts with US insurers as the iCARE dataset continues to grow.

Melbourne, Australia – 11 March 2026: [Adherium Limited](#) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® platform is pleased to announce further preliminary real-world outcomes from the groundbreaking iCARE respiratory care study.

The iCARE study is a large, real-world respiratory care study designed to evaluate how connected inhaler technology and remote monitoring can improve outcomes for patients with chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Following on from early data reported last year (ASX: 15 September 2026), new data was presented by study investigator, Kim Bennion of Intermountain Health at the Big Sky Pulmonary Conference in Montana on 5 March 2026. The analysis of ~850 Intermountain Health patients enrolled in the study between March 2024, and August 2025 reported the following positive clinical outcomes.

Key health economics outcomes (Mar 2024–Aug 2025):

- In line with the primary study objectives, there was a 67% reduction in patient hospitalisations, with inpatient encounters reducing from 3.27 to 0.93, per patient per year

- For those hospitalised, there was a 57% reduction in the length of stay
- There was a 46% reduction in total cost of care (down from \$28,235 to \$15,202), and
- An average of \$12,943 in annual savings were recorded, per patient

Dawn Bitz, CEO for Adherium commented: *“These outstanding early results underscore the impact that remote patient monitoring delivered through iCARE can have on patients’ lives, the healthcare system, and healthcare costs. We are very pleased with how the study is progressing and look forward to seeing more data presented at the American Thoracic Society 2026 International Conference from 15-20 May.”*

Strong adherence and sustained engagement between visits:

The iCARE program combines connected respiratory monitoring - enabled by Adherium’s Hailie® Smartinhaler® technology - with AI-driven behavioural engagement to support adherence and earlier intervention outside the clinic.

As released to the ASX on 15 September 2025, preliminary analysis of nearly 850 patients enrolled in the iCARE study indicates that more than 90% remain active participants. In a subset of patients using connected controller inhalers with at least 30 days of inhalation data, typical adherence was nearly two-thirds, and nearly four in ten achieving >80% adherence, a threshold linked with meaningfully fewer respiratory attacks.

In addition, iCARE demonstrated 54% persistence (“stickiness”) among active users of the over 14 months, suggesting sustained engagement even among older, higher-risk patients - an essential driver of value in chronic respiratory disease management.

A copy of the conference presentation can be viewed here: <https://www.umt.edu/big-sky-pulmonary/absolute-final-montana-kim-bennion-presentation-2-16-26.pdf#Bennion>

Program scale and upcoming dataset:

The iCARE study includes the deployment of 4,000 Hailie® Smartinhalers®, supporting up to 2,500 COPD and asthma patients across five Intermountain Health facilities over two years - underscoring the scalability of this model.

Additional analysis is planned, including outcomes by disease category (COPD vs. asthma), patient severity, and payor type, along with other drivers such as environmental and socioeconomic factors. A more comprehensive dataset is expected to be presented at the American Thoracic Society meeting 15-20 May 2026.

Together with growth of Adherium’s Remote Patient Monitoring channel, positive results from the iCARE program position the Company for new value-based contracts, expanded sales and reimbursement as healthcare systems and insurers increasingly seek technologies that improve outcomes and reduce costs.



ASX Release

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Adherium Limited

investors@adherium.com

Media Enquiries:

Haley Chartres

HACK Director

haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com

About Hailie® Smartinhaler®

Hailie® Smartinhaler® devices attach to commonly used inhalers to capture and transmit inhalation event data, enabling patients and care teams to understand medication-use patterns and support earlier, more proactive interventions.